肝门部胆管癌

预约门诊

生存率

肝门部胆管癌又称肝门周围胆管癌或克拉茨金瘤，是一种侵袭性癌症，常常在没有任何症状的情况下生长，直至阻塞胆管。由于患者多是在疾病已经扩散后才被确诊，因此总生存率一直较低。

术后

通过手术完全切除癌症（也就是常说的 R0 切除），是能带来长期生存机会的唯一治疗方法。如果在切除组织的边缘发现了癌细胞，则被称为 R1 或 R2 切除，生存率会降低。如果癌症已经扩散到淋巴结或血管，生存率也会降低。

如果癌症部位无法切除

如果无法进行手术，则治疗侧重于缓解症状和减缓癌症生长。预计这些疗法无法治愈癌症，但可以帮助改善生活质量并延长生存期。

治疗方法通常包括化疗或免疫疗法。通常首先考虑化疗，能否进行免疫疗法则取决于肿瘤的遗传特征。大多数患者即使接受治疗，也只能存活 6 到 12 个月。

肝移植后

有些患者的小型局部肿瘤无法切除，在专科中心进行肝移植或许是一个选项。这些患者的癌症尚未扩散到淋巴结或远处器官，而且对移植前的放化疗反应良好。部分患者接受移植后的结果可能好于手术，例如同时患有原发性硬化性胆管炎者。

申请预约
分期医生与科室
Jan. 20, 2026

Living with 肝门部胆管癌?

Connect with others like you for support and answers to your questions in the Sarcoma support group on Mayo Clinic Connect, a patient community.

Sarcoma Discussions

micky76
Chondrosarcoma: Anyone have above the knee amputation?

1 Replies Thu, Aug 13, 2026

Colleen Young, Connect Director
Diagnosed with sarcoma? Let's share

1083 Replies Mon, Aug 10, 2026

lessjudd1976
What treatments did you have for angiosarcoma?

7 Replies Mon, Aug 10, 2026

See more discussions
  1. Cameron JL, et al., eds. Management of intrahepatic, perihilar, and distal extrahepatic cholangiocarcinoma. In: Current Surgical Therapy. 14th ed. Elsevier; 2023. https://www.clinicalkey.com. Accessed Nov. 12, 2024.
  2. Feldman M, et al., eds. Tumors of the bile ducts, gallbladder, and ampulla. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 11th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed Nov. 12, 2024.
  3. Biliary tract cancers. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1517. Accessed Nov. 12, 2024.
  4. Bile duct cancer (cholangiocarcinoma) treatment — Health professional version (PDQ). National Cancer Institute. https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq. Accessed Nov. 12, 2024.
  5. Soares KC, et al. The Landmark Series: Hilar cholangiocarcinoma. Annals of Surgical Oncology. 2021; doi:10.1245/s10434-021-09871-6.
  6. Lowe RC, et al. Clinical manifestations and diagnosis of cholangiocarcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 12, 2024.
  7. Anderson CD. Surgical resection of localized cholangiocarcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 12, 2024.
  8. Anderson CD, et al. Adjuvant and neoadjuvant therapy for localized resectable cholangiocarcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 12, 2024.
  9. Anderson CD, et al. Treatment of locally advanced unresectable nonmetastatic cholangiocarcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 12, 2024.
  10. Palliative care. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1454. Accessed Nov. 12, 2024.
  11. Suarez-Munoz MA, et al. Risk factors and classifications of hilar cholangiocarcinoma. World Journal of Gastrointestinal Oncology. 2013; doi:10.4251/wjgo.v5.i7.132.
  12. Soares KC, et al. Hilar cholangiocarcinoma: Diagnosis, treatment options, and management. Hepatobiliary Surgery and Nutrition. 2014; doi:10.3978/j.issn.2304-3881.2014.02.05.
  13. MRCP (MR cholangiopancreatography). RadiologyInfo.org. https://www.radiologyinfo.org/en/info/mrcp. Accessed Nov. 18, 2024.
  14. Radioembolization (Y90). RadiologyInfo.org. https://www.radiologyinfo.org/en/info/radioembol. Accessed Dec. 5, 2024.
  15. Thermal ablation for tumor treatment. RadiologyInfo.org. https://www.radiologyinfo.org/en/info/thermal-ablation-therapy. Accessed Feb. 6, 2025.
  16. Breuer E, et al. Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? Results from an international benchmark study. Annals of Surgery. 2022; doi:10.1097/SLA.0000000000005641.
  17. Medical review (expert opinion). Mayo Clinic. Nov. 11, 2025.

相关

相关医疗程序

产品与服务

肝门部胆管癌